Adam I. Riker, MD


Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade

Adam J. Waxman, MD, MS


Dr. Waxman on the Future of Treatment in Multiple Myeloma

Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.

Adam M. Brufsky, MD


Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Adam M. Brufsky, MD, PhD


Audience Q&A: Future Directions in Breast Cancer Care

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.

Adam P. Dicker, MD, PhD


Dr. Dicker on DNA Sequencing for Prostate Cancer

Adam P. Dicker, MD, PhD, professor, chair, Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses DNA sequencing for patients with prostate cancer.

Adam S. Kibel, MD


Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers

Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.

Adam Scott Feldman, MD, MPH


Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active Surveillance

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.

Adel Kardosh, MD


Dr. Kardosh Discusses Epacadostat in Gastric/GEJ Adenocarcinoma

Adel Kardosh, MD, postdoctoral medical fellow, oncology, Stanford Medicine, discusses epacadostat in gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Adilia Hormigo, MD, PhD


Dr. Hormigo on the Current Treatment Landscape of Glioblastoma

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

Aditi Kumar, MD


Dr. Aditi Kumar on Aggressive Multimodal Therapy in Anaplastic Thyroid Cancer

Aditi Kumar, MD, endocrinology fellow at the University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer. A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.

Aditya Bardia, MD, MPH, Harvard Medical School


Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Aditya Bardia, MD, MPH, Massachusetts General Hospital


Treatment Advances in HR+ Advanced Breast Cancer

Aditya Bardia, MD, MPH, discusses the current standard of care for HR+ advanced breast cancer and reacts to treatment advances with the availability of CDK4/6 inhibitors.

Aditya Juloori, MD


Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Aditya V. Shreenivas, MD, MSCR


Keeping Ahead of Oncology Advances Requires Vigilance

Aditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.